CC-99677
oral, covalent MK2 inhibitor Ph. II candidate in ankylosing spondylitis from previously disclosed MK2 inhibitor and SBDD Transl Res, June 9, 2022 Bristol Myers Squibb, Princeton, NJ
Molecules of the Month - July 2022
4 minute read
Aug. 26, 2022
CC-99677: an Oral, Covalent MAPK–Activated Protein Kinase-2 (MK2) Inhibitor for Autoimmune Diseases